JP2007530546A - マトリックスメタロプロテイナーゼの非ペプチドインヒビター - Google Patents

マトリックスメタロプロテイナーゼの非ペプチドインヒビター Download PDF

Info

Publication number
JP2007530546A
JP2007530546A JP2007505043A JP2007505043A JP2007530546A JP 2007530546 A JP2007530546 A JP 2007530546A JP 2007505043 A JP2007505043 A JP 2007505043A JP 2007505043 A JP2007505043 A JP 2007505043A JP 2007530546 A JP2007530546 A JP 2007530546A
Authority
JP
Japan
Prior art keywords
compound
mmp
group
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530546A5 (cg-RX-API-DMAC10.html
Inventor
スブラマニアム アナンタン，
Original Assignee
サザン リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サザン リサーチ インスティチュート filed Critical サザン リサーチ インスティチュート
Publication of JP2007530546A publication Critical patent/JP2007530546A/ja
Publication of JP2007530546A5 publication Critical patent/JP2007530546A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
JP2007505043A 2004-03-22 2005-03-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター Pending JP2007530546A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55538004P 2004-03-22 2004-03-22
PCT/US2005/009263 WO2005092844A1 (en) 2004-03-22 2005-03-21 Nonpeptide inhibitors of matrix metalloproteinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011011407A Division JP2011079866A (ja) 2004-03-22 2011-01-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Publications (2)

Publication Number Publication Date
JP2007530546A true JP2007530546A (ja) 2007-11-01
JP2007530546A5 JP2007530546A5 (cg-RX-API-DMAC10.html) 2008-05-01

Family

ID=34963517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007505043A Pending JP2007530546A (ja) 2004-03-22 2005-03-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター
JP2011011407A Pending JP2011079866A (ja) 2004-03-22 2011-01-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011011407A Pending JP2011079866A (ja) 2004-03-22 2011-01-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Country Status (17)

Country Link
US (1) US8129406B2 (cg-RX-API-DMAC10.html)
EP (1) EP1735274B1 (cg-RX-API-DMAC10.html)
JP (2) JP2007530546A (cg-RX-API-DMAC10.html)
KR (1) KR20070046025A (cg-RX-API-DMAC10.html)
CN (1) CN101001834B (cg-RX-API-DMAC10.html)
AT (1) ATE449760T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005227311B2 (cg-RX-API-DMAC10.html)
CA (1) CA2560739A1 (cg-RX-API-DMAC10.html)
DE (1) DE602005017879D1 (cg-RX-API-DMAC10.html)
DK (1) DK1735274T3 (cg-RX-API-DMAC10.html)
ES (1) ES2338243T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA06010974A (cg-RX-API-DMAC10.html)
NZ (1) NZ550621A (cg-RX-API-DMAC10.html)
PL (1) PL1735274T3 (cg-RX-API-DMAC10.html)
PT (1) PT1735274E (cg-RX-API-DMAC10.html)
SI (1) SI1735274T1 (cg-RX-API-DMAC10.html)
WO (1) WO2005092844A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502964A (ja) * 2008-09-19 2012-02-02 ピムコ ２６６４ リミテッド アリール−フェニル−スルホンアミド−シクロアルキル化合物とその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293513B2 (en) 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
US20110200662A1 (en) * 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
WO2002055491A2 (en) * 2001-01-11 2002-07-18 Bristol Myers Squibb Company P 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)
JP2002535383A (ja) * 1999-01-27 2002-10-22 アメリカン・サイアナミド・カンパニー アセチレンβ−スルホンアミドおよびホスフィン酸アミドヒドロキサム酸ＴＡＣＥ阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
CZ294063B6 (cs) 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
NZ335053A (en) 1996-10-16 2000-10-27 American Cyanamid Co Beta-sulfonamido hydroxamic acids or ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase MMP and TACE (tumour necrosis factor, TNF, alpha converting enzyme) inhibitors
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IL131493A (en) * 1997-03-04 2004-05-12 Monsanto Co Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
JP2002535383A (ja) * 1999-01-27 2002-10-22 アメリカン・サイアナミド・カンパニー アセチレンβ−スルホンアミドおよびホスフィン酸アミドヒドロキサム酸ＴＡＣＥ阻害剤
WO2002055491A2 (en) * 2001-01-11 2002-07-18 Bristol Myers Squibb Company P 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502964A (ja) * 2008-09-19 2012-02-02 ピムコ ２６６４ リミテッド アリール−フェニル−スルホンアミド−シクロアルキル化合物とその使用

Also Published As

Publication number Publication date
KR20070046025A (ko) 2007-05-02
ES2338243T3 (es) 2010-05-05
ATE449760T1 (de) 2009-12-15
CN101001834A (zh) 2007-07-18
CN101001834B (zh) 2011-06-29
JP2011079866A (ja) 2011-04-21
PL1735274T3 (pl) 2010-05-31
AU2005227311A1 (en) 2005-10-06
CA2560739A1 (en) 2005-10-06
DK1735274T3 (da) 2010-03-29
EP1735274B1 (en) 2009-11-25
US20080312329A1 (en) 2008-12-18
WO2005092844A1 (en) 2005-10-06
AU2005227311B2 (en) 2012-03-15
DE602005017879D1 (de) 2010-01-07
MXPA06010974A (es) 2007-04-23
NZ550621A (en) 2009-11-27
US8129406B2 (en) 2012-03-06
EP1735274A1 (en) 2006-12-27
SI1735274T1 (sl) 2010-03-31
PT1735274E (pt) 2009-12-11

Similar Documents

Publication Publication Date Title
EP0977745B1 (en) Thioaryl sulfonamide hydroxamic acid compounds
JP2003500376A (ja) Ｘａ因子の阻害剤
CA2238175A1 (en) D-amino acid derived inhibitors of cysteine and serine proteases
PL198032B1 (pl) Pochodne amidów, sposób ich wytwarzania, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
JP2001518081A (ja) スルホニル２価アリールまたはヘテロアリールヒドロキサム酸化合物
NZ321293A (en) Sulfonamide inhibitors of matrix metalloproteinases
JP2010265276A (ja) ヒトａｄａｍ−１０インヒビター
JP2001521504A (ja) メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
HRP970474A2 (en) Compounds for and a method of inhibiting matrix metalloproteinases
JP2003500391A (ja) Ｘａ因子阻害剤
MXPA04000388A (es) Hidroximatos de sulfonilarilo y su uso como inhibidores de metaloproteinasas matriciales.
HUP0100597A2 (hu) Hidroxámsav- és karbonsavszármazékok
JP2011079866A (ja) マトリックスメタロプロテイナーゼの非ペプチドインヒビター
ES2281346T3 (es) Inhibidores de metaloproteinasas.
US20100234378A1 (en) Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
CA2384247A1 (en) Azacycloalkanone serine protease inhibitors
JP2005504026A (ja) スルホニルアリールまたはヘテロアリールヒドロキサム酸およびそれらの誘導体のアグリカナーゼ阻害剤としての使用
JP2003524007A (ja) アリールピペラジン類およびそれらのメタロプロテイナーゼ阻害剤（ｍｍｐ）としての使用
Oltenfreiter et al. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents
KR20010089617A (ko) 아세틸렌계 베타-설폰아미도 및 포스핀산 아미드하이드록삼산 티에이씨이 억제제
KR100242266B1 (ko) 캄포 구조를 갖는 신규한 트롬빈 억제제
KR100441635B1 (ko) 경구투여가가능한선택적트롬빈억제제
WO2001005389A2 (en) N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase
Isaac Analysis and Synthesis of Novel Inhibitors of MMPs and other Biological Targets
EP1417191A1 (en) Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802